{
    "ticker": "ANG.PRA",
    "name": "Angion Biomedica Corp.",
    "description": "Angion Biomedica Corp. is a biotechnology company focused on the development of innovative therapeutics for various diseases. Founded in 2007, Angion aims to address unmet medical needs through its proprietary drug discovery platform, which leverages advanced molecular biology techniques. The company's lead product candidates are designed to modulate the immune response and restore cellular function in conditions such as acute kidney injury and fibrotic diseases. Angion's commitment to research and development is evident in its collaborations with leading academic institutions and industry partners, enhancing its capabilities in drug development. With a strong pipeline of preclinical and clinical-stage programs, Angion is dedicated to improving patient outcomes and advancing the field of precision medicine. The company operates with a vision of transforming the landscape of treatment for serious health conditions, emphasizing safety and efficacy in its clinical trials. Through strategic partnerships and a focus on innovation, Angion is positioned to contribute significantly to the future of biopharmaceuticals.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2007",
    "website": "https://www.angion.com",
    "ceo": "Dr. Lawrence S. K. Wong",
    "social_media": {
        "twitter": "https://twitter.com/AngionBio",
        "linkedin": "https://www.linkedin.com/company/angion-biomedica-corp"
    },
    "investor_relations": "https://ir.angion.com",
    "key_executives": [
        {
            "name": "Dr. Lawrence S. K. Wong",
            "position": "CEO"
        },
        {
            "name": "Dr. Robert P. V. Jansen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ANG-3070",
                "ANG-8000"
            ]
        }
    ],
    "seo": {
        "meta_title": "Angion Biomedica Corp. | Innovative Biotechnology Solutions",
        "meta_description": "Explore Angion Biomedica Corp., a biotechnology company dedicated to developing innovative therapeutics for unmet medical needs. Learn about their advanced drug candidates and commitment to patient health.",
        "keywords": [
            "Angion Biomedica",
            "Biotechnology",
            "Pharmaceuticals",
            "Therapeutics",
            "Drug Development"
        ]
    },
    "faq": [
        {
            "question": "What does Angion Biomedica specialize in?",
            "answer": "Angion Biomedica specializes in the development of innovative therapeutics for diseases with unmet medical needs."
        },
        {
            "question": "Who is the CEO of Angion Biomedica?",
            "answer": "Dr. Lawrence S. K. Wong is the CEO of Angion Biomedica Corp."
        },
        {
            "question": "Where is Angion Biomedica headquartered?",
            "answer": "Angion Biomedica is headquartered in New York, New York, USA."
        },
        {
            "question": "What are Angion's main product candidates?",
            "answer": "Angion's main product candidates include ANG-3070 and ANG-8000, targeting various health conditions."
        },
        {
            "question": "When was Angion Biomedica founded?",
            "answer": "Angion Biomedica was founded in 2007."
        }
    ],
    "competitors": [
        "AMGN",
        "VRTX",
        "REGN"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "JNJ",
        "PFE"
    ]
}